Argatroban for anticoagulation during cardiopulmonary bypass in an infant

被引:17
作者
Dyke, PC
Russo, P
Mureebe, L
Russo, J
Tobias, JD [1 ]
机构
[1] Univ Missouri, Dept Anesthesiol, Russell & Mary Sheldon Chair Pediat Intens Care M, Columbia, MO 65212 USA
[2] Univ Missouri, Dept Cardiothorac Surg, Columbia, MO 65212 USA
[3] Univ Missouri, Dept Vasc Surg, Columbia, MO 65212 USA
[4] Univ Missouri, Dept Nursing, Columbia, MO 65212 USA
关键词
argatroban; heparin-induced thrombocytopenia; anticoagulation; cardiopulmonary bypass;
D O I
10.1111/j.1460-9592.2005.01417.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Heparin induced thrombocytopenia (HIT) is a rare, but potentially life-threatening complication of heparin therapy. In patients with HIT, alternative means of anticoagulation are necessary. The authors present an infant with HIT who required anticoagulation during cardiopulmonary bypass for tricuspid valve excision in the treatment of bacterial endocarditis. The direct thrombin inhibitor, argatroban, was successfully used. Previous reports regarding the use of argatroban and other nonheparin anticoagulants for anticoagulation are reviewed and suggestions regarding argatroban dosing in infants are presented.
引用
收藏
页码:328 / 333
页数:6
相关论文
共 38 条
[1]   Argatroban use during pediatric interventional cardiac catheterization [J].
Cetta, F ;
Graham, LC ;
Wrona, LL ;
Arruda, MJ ;
Walenga, JM .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 61 (01) :147-149
[2]   Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass [J].
Davis, Z ;
Anderson, R ;
Short, D ;
Garber, D ;
Valgiusti, A .
ANNALS OF THORACIC SURGERY, 2003, 75 (01) :264-265
[3]   Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: Heparin-induced thrombocytopenia in a high-risk cardiac surgical patient [J].
Edwards, JT ;
Hamby, JK ;
Worrall, NK .
ANNALS OF THORACIC SURGERY, 2003, 75 (05) :1622-1624
[4]   Hirudin in renal insufficiency [J].
Fischer, KG .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (05) :467-482
[5]   The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations [J].
Furukawa, K ;
Ohteki, H ;
Hirahara, K ;
Narita, Y ;
Koga, S .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (06) :1255-1256
[6]   Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia [J].
Gillis, S ;
Merin, G ;
Zahger, D ;
Deeb, M ;
Drenger, B ;
Hyam, E ;
Eldor, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (03) :657-659
[7]   Methods for the monitoring of direct thrombin inhibitors [J].
Hafner, G ;
Roser, M ;
Nauck, M .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (05) :425-430
[8]  
Herrman, 1996, J Thromb Thrombolysis, V3, P367
[9]   Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets [J].
Jeske, WP ;
Walenga, JM ;
Szatkowski, E ;
Ero, M ;
Herbert, JM ;
Haas, S ;
Bakhos, M .
THROMBOSIS RESEARCH, 1997, 88 (03) :271-281
[10]   Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia [J].
Kanagasabay, RR ;
Unsworth-White, MJ ;
Robinson, G ;
Bevan, D ;
Farnsworth, G ;
Haxby, EJ ;
Smith, EEJ .
ANNALS OF THORACIC SURGERY, 1998, 66 (02) :567-569